J C Martínez-Castrillo, I Pareés-Moreno, J L López Sendón-Moreno, P Pérez-Torre, S Fanjul, A Patiño-Patón, G García-Ribas, A Alonso-Cánovas
Revista de neurologia 2024 Jun 30Most patients with Parkinson's disease experience motor fluctuations or 'off' periods, which impact on their daily activities, increase their disability and diminish their quality of life. They suffer from these fluctuations despite multiple adjustments to the schedules, doses and intake of medication. In this context, on-demand or rescue treatments are necessary to attempt to improve 'off' periods, with drugs that have the pharmacokinetic advantage of a much faster onset of action because their routes of administration are not oral. There are currently three on-demand therapies for the treatment of fluctuations: subcutaneous apomorphine, inhaled levodopa and sublingual apomorphine. Of the three alternatives, subcutaneous apomorphine generally has the fastest onset of action, sublingual apomorphine provides the longest clinical effect, and inhaled levodopa has the most favourable side effect profile. Each of these drugs has its own characteristics: the time before onset of action, the duration of action and different side effect profiles. The choice for each patient will depend on their individual needs and circumstances. To mark the first year of the introduction of inhaled levodopa, we review these therapies, focusing on the experience with this new dosage form of levodopa.
J C Martínez-Castrillo, I Pareés-Moreno, J L López Sendón-Moreno, P Pérez-Torre, S Fanjul, A Patiño-Patón, G García-Ribas, A Alonso-Cánovas. Inhaled levodopa: from evidence to experience]. Revista de neurologia. 2024 Jun 30;78(S01):S1-S10
PMID: 38916176
View Full Text